

Clinical Development Pipeline

PROGRAM	TUMOR TYPE	SETTING	TREATMENT	PRECLINICAL	PHASE 1	PHASE 2	PHASE 3
Brentuximab Vedotin (ADCETRIS®)	Diffuse large B-cell lymphoma	R/R	SGN35-31: + lenalidomide, rituximab				
	Hodgkin lymphoma (HL)	1L	SGN35-27: + nivolumab, doxorubicin and dacarbazine				
	HL or PTCL (unfit for combination chemotherapy)	1L	SGN35-15: Monotherapy				
	HL and PTCL	R/R	SGN35-28: Retreatment				
	HL (pediatrics)	R/R	CheckMate 744: + nivolumab				
Enfortumab Vedotin-efv (PADCEV®)	Locally advanced or metastatic urothelial cancer	1L	EV-302: + pembrolizumab, +/- chemotherapy				
			EV-301: Post PD(L)-1 and post platinum chemotherapy				Enrollment Complete
			EV-201: Cohort 2 post anti-PD(L)-1 or post PDF(L)-1 inhibitor, platinum naive and cisplatin ineligible			Enrollment Complete	Pivotal
		1L/2L	EV-103: +/- pembrolizumab or other anti-cancer agents				
	Muscle invasive bladder cancer	1L*	EV-303/KEYNOTE-905: + pembrolizumab				
Locally advanced or metastatic solid tumors		EV-103: +/- pembrolizumab					
			EV-202: Monotherapy				
Tucatinib (TUKYSA®)	HER2+ metastatic breast cancer	1L/2L	HER2CLIMB-02: + T-DM1				
	HER2+ metastatic colorectal cancer	R/R	MOUNTAINEER: + trastuzumab				Pivotal
	HER2+ gastric cancer	1L	+ trastuzumab, oxaliplatin				
Tisotumab Vedotin	Metastatic/recurrent cervical cancer	R/R	innovaTV 204: Monotherapy			Top-line Data Reported	
		1L	innovaTV 205: + other anti-cancer agents				Pivotal
	Metastatic solid tumors	R/R	innovaTV 207: Monotherapy				
	Platinum-resistant ovarian cancer	2L	innovaTV 208: Monotherapy				
Ladiratumumab Vedotin	Metastatic triple-negative breast cancer	1L	+ pembrolizumab				
	Metastatic breast cancer (HR+/HER2-)	R/R	+ trastuzumab				
	Metastatic solid tumors	R/R	Monotherapy				
SEA-BCMA SEA-CD40 SGN-CD228A SEA-CD70 SEA-TGT SGN-B6A SGN-CD30C	Multiple myeloma	R/R	+/- dexamethasone				
	Pancreatic cancer	R/R	+/- pembrolizumab, gemcitabine, nap-paclitaxel				
	Solid tumors	R/R	Monotherapy				
	MDS / AML	R/R	Monotherapy				
	Solid tumors and lymphoma	R/R	+/- pembrolizumab				
	Solid tumors	R/R	Monotherapy				
Lymphoma							

1L: frontline/first-line
 2L: second-line
 R/R: relapsed/refractory
 PTCL: peripheral T-cell lymphoma

*May have received prior intravesical Bacillus Calmette-Guerin (BCG) or intravesical chemotherapy